Statin use and the risk of incident dementia: The Cardiovascular Health Study

Archives of Neurology

Volumn 62, Issue 7, 2005, Pages 1047-1051

  Rea, Thomas D ^a   Breitner, John C ^a,b   Psaty, Bruce M ^a   Fitzpatrick, Annette L ^a   Lopez, Oscar L ^c   Newman, Anne B ^c   Hazzard, William R ^a,b   Zandi, Peter P ^d   Burke, Gregory L ^f   Lyketsos, Constantine G ^e   Bernick, Charles ^g   Kuller, Lewis H ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Veterans Administration   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK FACTOR; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; HYPERLIPIDEMIA;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE;

EID: 22844431778     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.7.1047     Document Type: Article

References (21)

1. Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementias. Neurology. 1985;35:834-840.
2. Ritchie K, Lovestone S. The dementias. Lancet. 2002;360:1759-1766.
3. Kukull WA, Ganguli M. Epidemiology of dementia. Neurol Clin. 2000;18:923-949.
4. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:131-136.
5. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular disease reduction. JAMA. 1998;279:1643-1650.
6. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856-5861.
7. Naidu A, Xu Q, Catalano R, Cordell B. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res. 2002;958:100-111.
8. Refolo LM, Pappolla J, LaFrancois L, et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2001;8:890-899.
9. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
10. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
11. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
12. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57:M414-M418.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
14. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
15. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M; Cardiovascular Health Study Collaborative Research Group. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683-692.
16. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker J, Beauchamp N. Evaluation of dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology. 2003;22:1-12.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
18. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42(3,pt 1):473-480.
19. Corsini A, Bellosta S, Baetta R. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
20. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry. 1987;48:314-318.
21. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50:1852-1856.